The treatment of deep vein thrombosis and pulmonary embolism

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 489-496

  Turkstra, Franktien ^a   Koopman, Maria M W ^a   Büller, Harry R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

CONFERENCE PAPER; CONSERVATIVE TREATMENT; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; LUNG EMBOLISM; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; THROMBECTOMY;

EID: 0030804841     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657575     Document Type: Conference Paper

References (76)

1. Huisman MV, Büller HR, ten Cate JW, van Royen EA, Kersten MJ, Baks R. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95:498-502.
2. Dorfman GS, Cronan JJ, Tupper TB, Messersmith RN, Denny DF, Lee CH. Occult pulmonary embolism: a common occurrence in patients with deep venous thrombosis. AJR 1987; 148:263-6.
3. Doyle DJ, Turpie AGG, Hirsh J, Best C, Kinch D, Levine MN, Gent M. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987; 107:441-5.
4. Hull RD, Hirsh J, Carter CJ, Jay RJ, Dodd PE, Ockelford PA, et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Int Med 1983; 98:891-99.
5. Kruit VMJ, de Boer AC, Sing AK, van Roon F. The significance of venography in the management of patients with clinically suspected pulmonary embolism. J Intern Med 1991; 230:333-9.
6. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, et al. The long-term clinical course of acute deep vein thrombosis. Annals 1996; 125:1-7.
7. Byeth RJ et al. Long term outcomes of patients with deep vein thrombosis. Arch Int Med 1995; 155:1031-7.
8. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326:1240-5.
9. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67:639-43.
10. Thery C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, d'Azemar P, Coquart JP. Randomised trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 1992; 85:1380-9.
11. Kuijer PMM, Gallus AS, Cade JF, Buller HR. A randomised comparison of LMWH versus standard heparin in the initial treatment of pulmonary embolism. Thromb Haemost 1995; 73:974 (abstract).
12. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. Blood 1996; 88:626 (abstract).
13. Mahomer H, Castleberry JW, Coleman WO. Attempts to restore function in major veins which are the site of massive thrombosis. Annals Surg 1957; 146:510-22.
14. Mavor GE. Deep vein thrombosis. Surgical Management. Br Med J 1969; 4:680-2.
15. Haller JA, Abrams BL. Use of thrombectomy in the treatment of acute iliofemoral venous thrombosis in forty-five patients. Ann Surg 1963; 158:561-6.
16. Lansing AM, Davis WM. Five-year follow-up study of iliofemoral venous thrombectomy. Ann Surg 1968; 4:620-6.
17. Johanssen E, Nordlander S, Zetterquist S. Venous thrombectomy in the lower extremity-clinical, phlebographic and plethysmographic evaluation of early and late results. Acta Chir Scand 1973; 139:511-6.
18. Young AE, Thomas ML, Browse NL. Comparison between sequelae of surgical and medical treatment of venous thromboembolism. Br Med J 1974; 4:127-30.
19. Prager M, Huk I, Kretschmer G, Polterauer P. Chirurgische Therapie der akuten BeinBecken-Venen thrombose. Acta Med Austriaca 1994; 21:102-4.
20. Mickley V, Friedrich JM, Hutschenreiter S, Sunder-Plassmann L. Langzeitergebnisse nach perkutan-transluminaler Angioplastie und Stentimplantation bei venbsen Stenosen nach transfemoraler Thrombektomie. Vasa 1993; 22:44-52.
21. Kniemeyer HW, Sandmann W, Schwindt C, Grabitz K, Torsello G, Stühmeier K. Thrombectomy with arteriovenous fistula for embolizing deep venous thrombosis: an alternative therapy for prevention of recurrent pulmonary embolism. Clin Invest 1993; 72:40-5.
22. Plate G, Einarsson E, Ohlin P, Jensen R, Qvarfordt P, Eklöf B. Thrombectomy with temporary arteriovenous fistula: The treatment of choice in acute iliofemoral venous thrombosis. J Vasc Surg 1984; 1:867-76.
23. Plate G, Akesson H, Einarsson E, Ohlin P, Eklof B. Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula. Eur J Cardiovasc Surg 1990; 4:483-9.
24. Jakob H, Vahl C, Lange R, Micek M, Tanzeem A, Hagl S. Modified surgical concept for fulminant pulmonary embolism. Eur J Cardio-throac Surg 1995; 9:557-61.
25. Meyer G, Tamisier D, Sors H, et al. Pulmonary embolectomy: a 20-year experience at one centre. Ann Thorac Surg 1991; 51: 232-6.
26. Robertson BR, Nilsson IM, Nylander G. Value of streptokinase and heparin in treatment of acute deep venous thrombosis. Acta Chir Scand 1968; 134:203-8.
27. Kakkar VV, Flanc C, Howe CT, O'Shea M, Flute P.T. Treatment of deep vein thrombosis. A trial of heparin, streptokinase, and Alvin. Br Med J 1969; 1:806-10.
28. Robertson BR, Nilsson IM, Nylander G. Thrombolytic effect of streptokinase as evaluated by phlebography of deep venous thrombi of the leg. Acta Chri Scand 1970; 136:173-80.
29. Tsapogas MJ, Peabody RA, Wu KT, Karmody AM, Devaraj KT, Eckert C. Controlled study of thrombolytic therapy in deep vein thrombosis. Surgery 1973; 74:973-84.
30. Porter JM, Seaman AJ, Common HH, Rosch J, Eidemiller LR, Calhoun AD. Comparison of heparin and streptokinase in the treatment of venous thrombosis. Am Surg 1975; 41:511-9.
31. Elliot MS, Immelman EJ, Jeffery P, Benatar SR, Funstone MR, Smith JA, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg 1979; 66: 838-43.
32. Kakkar VV, Lawrence D. Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis. Am J Surg 1985; 150:54-63.
33. Schulman S, Granqvist S, Juhlin-Dannfelt A, Lockner D. Long-term sequelae of calf vein thrombosis treated with heparin or low-dose streptokinase. Acta Med Scand 1986; 219:349-57.
34. Goldhaber SZ, Meyerovitz MF, Green D, Vogelzang RL, Citrin P, Heit J, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990; 88:235-40.
35. Turpie AGG, Levine MN, Hirsh J, Ginsberg JS, Cruickshank M, Jay R, Gent M. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis Chest 1990; 97:172S5S.
36. Lensing AWA, Hirsh J. Rationale and results of thrombolytic therapy for deep vein thrombosis. In: Vascular Diagnosis. Bernstein EF (eds). Mosby-Year Book, St Louis 1993; pp. 875-9.
37. The Urokinase Pulmonary Embolism Trial. A national cooperative study. Am Heart J 1973; 47 (suppl 2):1-108.
38. Dalia-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, Zonzin P, Zanuttini D, Barbaresi F, Agnelli G, Morpurgo M, Marini MG, Visani L. PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator multicenter study 2. J Am Coll Cardiol 1992; 20:520-6.
39. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98:1473-79.
40. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva A, Come PC, Lee RT, Parker JA, Mogtader A, McDonough J, Braunwald E. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right ventricular function and pulmonary perfusion. Lancet 1993; 341:507-11.
41. Hirsh J. Heparin. N Engl J Med 1991; 324:1565-74.
42. Brandjes DPM, Heijboer H, Büller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992; 327:1485-9.
43. Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Int Med 1992; 116:279-84.
44. Hull RD, Raskob GE, Hirsh J et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. New Engl J Med 1986; 315:1109-14.
45. Gallus A, Jackaman J, Tillet J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 2:1293-6.
46. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. New Engl J Med 1972; 287:325-7.
47. Cruickshank MY, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151:333-7.
48. Hirsh J, Levine NW. Low molecular weight heparin. Blood 1992; 79:1-17.
49. Lensing AWA, Hirsh J, Buller HR. Diagnosis of venous thrombosis. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, Coleman RW, Hirsh J, Marder VJ, Salzman EW (eds). Lippincott, Philadelphia 1982; pp. 1297-321.
50. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep vein thrombosis? Ann Intern Med 198 1; 94:439-44.
51. Lagerstedt Cl, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2:515-8.
52. Hull RD, Hirsh J, Carter C, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis: A randomized trial. Ann Intern Med 1985; 102:21-6.
53. Huisman MV, Buller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med 1986; 314:823-6.
54. Heijboer H, Buller HR, Lensing AWA, Turpie AGO, Colly LP, ten Cate JW. A comparison of real-time ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med 1993; 329:1365-9.
55. Sluzewski M, Koopman MMW, Schuur KH, Vroonhoven ThJMV, van Ruijs JHJ. Influence of negative ultrasound findings on the management of in- and outpatients with suspected deep-vein thrombosis. Eur J Radiol 1991; 13:174-7.
56. Hull RD, Raskob GE, Coates G, Panju AA, Gill GJ. A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med 1989; 149:2549-55.
57. Hull RD, Raskob GE, Ginsberg JS, Panju AA, Brill-Edwards P, Coates G, et al. A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Int Med 1994; 154:289-97.
58. Wells P, Ginsberg J, Anderson D, Hirsh J, Turpie A, Bormanis J, Kearon C, Weitz J. The use of a clinical model in a prospective management study of patients with suspected pulmonary embolism. Blood 1996; 88:625s (abstract).
59. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
60. Prandoni P, Lensing AWA, Büller RR et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339:441-5.
61. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, d'Azemar P, Büller M on behalf of the TASMAN-study group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334:682-7.
62. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68:14-8.
63. Lindmarker P, Holmström M, Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72:186-90.
64. Fiessinger JN, Fernandez ML, Gatterer E, Ohlsson CG. Fragmin once daily versus continuous infusion of heparin in the treatment of DVT - A European Multicentre Trial. Haemost 1994; 24(suppl I):44.
65. Luomanmaki K and the Finnish multicentre group, Hallert C, Kim H. LMWH (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemaost 1994; 24(suppl I):248.
66. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment of proximal vein thrombosis. Arch Intern Med 1993; 153:1541-6.
67. Levine MN, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996; 334:677-81.
68. Hull, RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326:975-81.
69. Duroux P. A collaborative European Multicentre Study: a randomised trial of subcutaneous LMWH (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991; 65:251-6.
70. Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between LMWH (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985; 54:813-7.
71. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Loerum F, Scheel B, Sortland O, Vinje B. Subcutaneous treatment of deep venous thrombosis: a comparison of unfractionated and LMWH. Haemost 1986; 16(suppl):30-7.
72. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis. Thromb Haemost 1990; 64:506-10.
73. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Eng J Med 1995; 332: 1330-5.
74. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996; 335:1816-28.
75. Meyer G, Brenot F, Pacouret G, Simonneau G, Gillet Juvin K, Charbonnier B, Sors H. Subcutaneous low-molecular-weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of non massive pulmonary embolism: an open randomised pilot study. Thromb Haemostas 1995; 74:1432-5.
76. Simonneau G, Sors H, Charbonnier B, Beau B, for the THESEE group. Once daily low molecular weight heparin (LMWH) Tinzaparin versus unfractionated heparin (UFH) in the treatment of pulmonary embolism (PE). Haemostasis 1996; 26 (suppl 3):006 (abstract).